自己免疫性モノクローナル抗体の世界市場レポート 2025年

自己免疫性モノクローナル抗体の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で988億1,000万米ドルに成長します。予測期間中の成長は、個別化医療に対する需要の高まり、バイオシミラーの採用増加、自己免疫治療における臨床試験の拡大、高齢者人口の増加、慢性免疫疾患の有病率の上昇など、いくつかの要因に起因しています。この間の主な動向としては、抗体工学の進展、二重特異性抗体の開発、創薬における人工知能の利用の拡大、治療計画におけるゲノミクスの統合、新規ドラッグデリバリーシステムの台頭などが挙げられます。

生物製剤に対する需要の高まりは、今後数年間の自己免疫性モノクローナル抗体市場の拡大を牽引すると予想されます。生物製剤とは、生物またはその成分に由来する医療用製品を指し、疾患の治療、予防、診断に用いられます。生物製剤の需要が増加しているのは、がん、自己免疫疾患、遺伝性疾患など、従来の治療法では効果が期待できない複雑な疾患を効果的に治療できることが主な理由です。自己免疫モノクローナル抗体は、標的免疫調節を提供することで生物製剤による治療を強化し、過剰な免疫反応を管理するのに有効です。これらの治療法は、正確な治療を提供し、患者の転帰を改善し、副作用を最小限に抑えることにより、広範な免疫抑制剤への依存を軽減します。例えば、2024年6月、米国のヘルスケア企業であるCardinal Health Inc.は、2023年にFDAが承認したバイオシミラー製品が40品目あり、そのうち25品目が米国市場で市販されていると報告し、2022年のバイオシミラー製品33品目から増加しています。このため、生物製剤に対する需要の高まりが自己免疫性モノクローナル抗体市場の成長を牽引しています。

自己免疫性モノクローナル抗体市場の主要企業は、安全性、有効性、品質を高めるため、バイオシミラーなどの革新的ソリューションの開発に注力しています。バイオシミラー開発では、高度なバイオテクノロジー、厳格な試験、臨床研究を通じて安全性、有効性、品質を確保しながら、既存の承認済み生物製剤と類似性の高い生物製剤を創出します。例えば、2025年2月、インドのバイオ医薬品会社であるBiocon Biologics Limitedは、クローン病、潰瘍性大腸炎、乾癬などの自己免疫疾患の治療薬として開発されたバイオシミラー「YESINTEK」を上市しました。YESINTEKは、インターロイキン-12およびインターロイキン-23の活性を阻害することにより、炎症を抑制し、免疫反応を制御します。基準製品であるステラーラを模倣することで、YESINTEKは、生物製剤への患者アクセスを改善しながら、長期的な疾患管理に貢献します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の自己免疫性モノクローナル抗体のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の自己免疫性モノクローナル抗体市場：成長率分析
• 世界の自己免疫性モノクローナル抗体市場の実績：規模と成長、2019～2024年
• 世界の自己免疫性モノクローナル抗体市場の予測：規模と成長、2024～2029年、2034年
• 世界の自己免疫性モノクローナル抗体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の自己免疫性モノクローナル抗体市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫グロブリンGモノクローナル抗体
• 免疫グロブリンMモノクローナル抗体
• キメラモノクローナル抗体
• 完全ヒトモノクローナル抗体
• 世界の自己免疫性モノクローナル抗体市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮下
• 静脈内
• 筋肉内
• 世界の自己免疫性モノクローナル抗体市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 関節リウマチ
• 多発性硬化症
• 全身性エリテマトーデス
• 乾癬
• 炎症性腸疾患
• 世界の自己免疫性モノクローナル抗体市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の自己免疫性モノクローナル抗体市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 外来診療所
• 在宅ケア設定
• 研究機関
• 世界の自己免疫性モノクローナル抗体市場：免疫グロブリンG（IgG）モノクローナル抗体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫グロブリンG1（IgG1）
• 免疫グロブリンG2（IgG2）
• 免疫グロブリンG3（IgG3）
• 免疫グロブリンG4（IgG4）
• 世界の自己免疫性モノクローナル抗体市場：免疫グロブリンM（IgM）モノクローナル抗体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 五量体免疫グロブリンM（IgM）
• 六量体免疫グロブリンM（IgM）
• 世界の自己免疫性モノクローナル抗体市場：キメラモノクローナル抗体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• マウス可変領域+ ヒト定常領域
• ヒト化可変領域+ マウス定常領域
• 世界の自己免疫性モノクローナル抗体市場：完全ヒトモノクローナル抗体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ファージディスプレイ由来
• トランスジェニックマウス由来
• 完全ヒトハイブリドーマ由来

第7章 地域別・国別分析

• 世界の自己免疫性モノクローナル抗体市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の自己免疫性モノクローナル抗体市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 自己免疫性モノクローナル抗体市場：競合情勢
• 自己免疫性モノクローナル抗体市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• UCB S.A.
• Genmab A/S
• Zymeworks Inc.
• Xencor Inc.
• Immutep Limited
• Cue Biopharma Inc.
• Santa Ana Bio Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 自己免疫性モノクローナル抗体市場2029年：新たな機会を提供する国
• 自己免疫性モノクローナル抗体市場2029年：新たな機会を提供するセグメント
• 自己免疫性モノクローナル抗体市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Autoimmune monoclonal antibodies are laboratory-created proteins designed to target specific components of the immune system involved in autoimmune diseases. These antibodies help regulate or block abnormal immune responses that mistakenly attack the body's own tissues. Their primary purpose is to reduce inflammation and prevent the immune system from attacking healthy tissues, thereby minimizing damage and maintaining normal physiological function.

The main types of autoimmune monoclonal antibodies include Immunoglobulin G (IgG) monoclonal antibodies, Immunoglobulin M (IgM) monoclonal antibodies, chimeric monoclonal antibodies, and fully human monoclonal antibodies. IgG monoclonal antibodies are lab-engineered proteins that specifically target and bind to molecules in the body, regulating immune responses to provide precise and prolonged therapeutic effects in autoimmune treatments. These antibodies can be administered through various routes, including subcutaneous, intravenous, and intramuscular. They are used to treat conditions such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, and inflammatory bowel disease. Distribution channels for these antibodies include hospital pharmacies, online pharmacies, and retail pharmacies. The primary end-users of these therapies include hospitals, outpatient clinics, homecare settings, and research institutions.

The autoimmune monoclonal antibody market research report is one of a series of new reports from The Business Research Company that provides autoimmune monoclonal antibody market statistics, including the autoimmune monoclonal antibody industry global market size, regional shares, competitors with the autoimmune monoclonal antibody market share, detailed autoimmune monoclonal antibody market segments, market trends, and opportunities, and any further data you may need to thrive in the autoimmune monoclonal antibody industry. This autoimmune monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autoimmune monoclonal antibody market size has grown strongly in recent years. It will grow from $65.83 billion in 2024 to $71.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to several factors, including the increasing prevalence of autoimmune diseases, the growing use of biologics in treatment, rising awareness of targeted therapies, early approvals of monoclonal antibody drugs, and the expansion of healthcare access in developed countries.

The autoimmune monoclonal antibody market size is expected to see strong growth in the next few years. It will grow to $98.81 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to several factors, including the increasing demand for personalized medicine, rising adoption of biosimilars, expansion of clinical trials in autoimmune therapy, a growing geriatric population, and the rising prevalence of chronic immune disorders. Key trends during this period include advancements in antibody engineering, the development of bispecific antibodies, the growing use of artificial intelligence in drug discovery, the integration of genomics in treatment planning, and the emergence of novel drug delivery systems.

The growing demand for biologics is expected to drive the expansion of the autoimmune monoclonal antibody market in the coming years. Biologics refer to medical products derived from living organisms or their components, used for the treatment, prevention, or diagnosis of diseases. The increasing demand for biologics is largely due to their ability to effectively treat complex conditions such as cancer, autoimmune disorders, and genetic diseases, where traditional therapies may not be as effective. Autoimmune monoclonal antibodies enhance biologic treatments by providing targeted immune modulation, making them effective in managing overactive immune responses. These therapies reduce the reliance on broad immunosuppressants by offering precise treatment, improving patient outcomes, and minimizing side effects. For example, in June 2024, Cardinal Health Inc., a US-based healthcare company, reported that there were 40 FDA-approved biosimilar products in 2023, 25 of which were commercially available in the US market, an increase from 33 biosimilar products in 2022. Therefore, the rising demand for biologics is driving the growth of the autoimmune monoclonal antibody market.

Leading companies in the autoimmune monoclonal antibody market are focusing on developing innovative solutions, such as biosimilars, to enhance safety, efficacy, and quality. Biosimilar development involves creating biological products that are highly similar to existing approved biologics, ensuring safety, efficacy, and quality through advanced biotechnology, rigorous testing, and clinical studies. For example, in February 2025, Biocon Biologics Limited, an India-based biopharmaceutical company, launched YESINTEK, a biosimilar designed to treat autoimmune diseases such as Crohn's disease, ulcerative colitis, and psoriasis. YESINTEK targets and inhibits the activity of interleukin-12 and interleukin-23 to reduce inflammation and regulate immune responses. By mimicking the reference product Stelara, YESINTEK helps manage long-term disease while improving patient access to biologic therapies.

In June 2023, Merck & Co., a US-based pharmaceutical company, acquired Prometheus Biosciences, Inc. for approximately $10.8 billion. This acquisition allows Merck to accelerate the development of precision medicine in immunology by utilizing Prometheus' technology, data analytics, and the TL1A-targeting candidate PRA023 to address unmet needs in immune-mediated diseases. Prometheus Biosciences, Inc. is a US-based biotechnology company specializing in providing autoimmune monoclonal antibodies.

Major players in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc.

North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in autoimmune monoclonal antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the autoimmune monoclonal antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autoimmune monoclonal antibody market consists of sales of adalimumab (humira), etanercept (enbrel), infliximab (remicade), rituximab (rituxan), tocilizumab (actemra), belimumab (benlysta), and secukinumab (cosentyx). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autoimmune Monoclonal Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autoimmune monoclonal antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autoimmune monoclonal antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autoimmune monoclonal antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Immunoglobulin G Monoclonal Antibodies; Immunoglobulin M Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Fully Human Monoclonal Antibodies
• 2) By Route Of Administration: Subcutaneous; Intravenous; Intramuscular
• 3) By Application: Rheumatoid Arthritis; Multiple Sclerosis; Systemic Lupus Erythematosus; Psoriasis; Inflammatory Bowel Disease
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Outpatient Clinics; Homecare Settings; Research Institutions
• Subsegments:
• 1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1); Immunoglobulin G2 (IgG2); Immunoglobulin G3 (IgG3); Immunoglobulin G4 (IgG4)
• 2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM); Hexameric Immunoglobulin M (IgM)
• 3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region; Humanized Variable Region + Murine Constant Region
• 4) By Fully Human Monoclonal Antibodies: Phage Display-Derived; Transgenic Mouse-Derived; Fully Human Hybridoma-Derived
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd; Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Autoimmune Monoclonal Antibody Market Characteristics

3. Autoimmune Monoclonal Antibody Market Trends And Strategies

4. Autoimmune Monoclonal Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Autoimmune Monoclonal Antibody Growth Analysis And Strategic Analysis Framework

• 5.1. Global Autoimmune Monoclonal Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Autoimmune Monoclonal Antibody Market Growth Rate Analysis
• 5.4. Global Autoimmune Monoclonal Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Autoimmune Monoclonal Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Autoimmune Monoclonal Antibody Total Addressable Market (TAM)

6. Autoimmune Monoclonal Antibody Market Segmentation

• 6.1. Global Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulin G Monoclonal Antibodies
• Immunoglobulin M Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• Fully Human Monoclonal Antibodies
• 6.2. Global Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• Intramuscular
• 6.3. Global Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Multiple Sclerosis
• Systemic Lupus Erythematosus
• Psoriasis
• Inflammatory Bowel Disease
• 6.4. Global Autoimmune Monoclonal Antibody Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Autoimmune Monoclonal Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Outpatient Clinics
• Homecare Settings
• Research Institutions
• 6.6. Global Autoimmune Monoclonal Antibody Market, Sub-Segmentation Of Immunoglobulin G (IgG) Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunoglobulin G1 (IgG1)
• Immunoglobulin G2 (IgG2)
• Immunoglobulin G3 (IgG3)
• Immunoglobulin G4 (IgG4)
• 6.7. Global Autoimmune Monoclonal Antibody Market, Sub-Segmentation Of Immunoglobulin M (IgM) Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pentameric Immunoglobulin M (IgM)
• Hexameric Immunoglobulin M (IgM)
• 6.8. Global Autoimmune Monoclonal Antibody Market, Sub-Segmentation Of Chimeric Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Murine Variable Region + Human Constant Region
• Humanized Variable Region + Murine Constant Region
• 6.9. Global Autoimmune Monoclonal Antibody Market, Sub-Segmentation Of Fully Human Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phage Display-Derived
• Transgenic Mouse-Derived
• Fully Human Hybridoma-Derived

7. Autoimmune Monoclonal Antibody Market Regional And Country Analysis

• 7.1. Global Autoimmune Monoclonal Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Autoimmune Monoclonal Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Autoimmune Monoclonal Antibody Market

• 8.1. Asia-Pacific Autoimmune Monoclonal Antibody Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Autoimmune Monoclonal Antibody Market

• 9.1. China Autoimmune Monoclonal Antibody Market Overview
• 9.2. China Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Autoimmune Monoclonal Antibody Market

• 10.1. India Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Autoimmune Monoclonal Antibody Market

• 11.1. Japan Autoimmune Monoclonal Antibody Market Overview
• 11.2. Japan Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Autoimmune Monoclonal Antibody Market

• 12.1. Australia Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Autoimmune Monoclonal Antibody Market

• 13.1. Indonesia Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Autoimmune Monoclonal Antibody Market

• 14.1. South Korea Autoimmune Monoclonal Antibody Market Overview
• 14.2. South Korea Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Autoimmune Monoclonal Antibody Market

• 15.1. Western Europe Autoimmune Monoclonal Antibody Market Overview
• 15.2. Western Europe Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Autoimmune Monoclonal Antibody Market

• 16.1. UK Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Autoimmune Monoclonal Antibody Market

• 17.1. Germany Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Autoimmune Monoclonal Antibody Market

• 18.1. France Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Autoimmune Monoclonal Antibody Market

• 19.1. Italy Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Autoimmune Monoclonal Antibody Market

• 20.1. Spain Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Autoimmune Monoclonal Antibody Market

• 21.1. Eastern Europe Autoimmune Monoclonal Antibody Market Overview
• 21.2. Eastern Europe Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Autoimmune Monoclonal Antibody Market

• 22.1. Russia Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Autoimmune Monoclonal Antibody Market

• 23.1. North America Autoimmune Monoclonal Antibody Market Overview
• 23.2. North America Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Autoimmune Monoclonal Antibody Market

• 24.1. USA Autoimmune Monoclonal Antibody Market Overview
• 24.2. USA Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Autoimmune Monoclonal Antibody Market

• 25.1. Canada Autoimmune Monoclonal Antibody Market Overview
• 25.2. Canada Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Autoimmune Monoclonal Antibody Market

• 26.1. South America Autoimmune Monoclonal Antibody Market Overview
• 26.2. South America Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Autoimmune Monoclonal Antibody Market

• 27.1. Brazil Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Autoimmune Monoclonal Antibody Market

• 28.1. Middle East Autoimmune Monoclonal Antibody Market Overview
• 28.2. Middle East Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Autoimmune Monoclonal Antibody Market

• 29.1. Africa Autoimmune Monoclonal Antibody Market Overview
• 29.2. Africa Autoimmune Monoclonal Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Autoimmune Monoclonal Antibody Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Autoimmune Monoclonal Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Autoimmune Monoclonal Antibody Market Competitive Landscape And Company Profiles

• 30.1. Autoimmune Monoclonal Antibody Market Competitive Landscape
• 30.2. Autoimmune Monoclonal Antibody Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Autoimmune Monoclonal Antibody Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Regeneron Pharmaceuticals Inc.
• 31.9. UCB S.A.
• 31.10. Genmab A/S
• 31.11. Zymeworks Inc.
• 31.12. Xencor Inc.
• 31.13. Immutep Limited
• 31.14. Cue Biopharma Inc.
• 31.15. Santa Ana Bio Inc.

32. Global Autoimmune Monoclonal Antibody Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autoimmune Monoclonal Antibody Market

34. Recent Developments In The Autoimmune Monoclonal Antibody Market

35. Autoimmune Monoclonal Antibody Market High Potential Countries, Segments and Strategies

• 35.1 Autoimmune Monoclonal Antibody Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Autoimmune Monoclonal Antibody Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Autoimmune Monoclonal Antibody Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer